Valneva SE (VLA)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
€3.562
Buy
€3.60
€-0.138 (-3.73%)
Prices updated at 16 Dec 2025, 16:35 CET
| Prices minimum 15 mins delay
Prices in EUR
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes two vaccines for travelers; one for the prevention of Japanese encephalitis (IXIARO) and the second (DUKORAL) for the prevention of cholera and diarrhoea.
-0.61%
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Profit margins
Valuation
Profit margins data table
Year | Gross margin (%) |
|---|---|
| 2024 | 41.89 |
| 2023 | 34.37 |
| 2022 | 10.20 |
| 2021 | 46.01 |
| 2020 | 50.78 |
| 2019 | 58.18 |
| 2018 | 60.68 |
| 2017 | 56.72 |
| 2016 | 54.20 |
| 2015 | 40.07 |
Valuation data table
Year | Price / Sales |
|---|---|
| 2025 | 3.46 |
| 2024 | 1.96 |
| 2023 | 2.93 |
| 2022 | 1.24 |
| 2021 | 20.61 |
| 2020 | 7.38 |
| 2019 | 1.78 |
| 2018 | 2.36 |
| 2017 | 2.08 |
| 2016 | 2.69 |
| 2015 | 3.84 |
Price/Forward earnings (YTD)
-30.86
Returns
Debt profile
Returns data table
Year | Return on assets (%) |
|---|---|
| 2024 | -2.55 |
| 2023 | -18.76 |
| 2022 | -19.92 |
| 2021 | -11.59 |
| 2020 | -18.04 |
| 2019 | -0.71 |
| 2018 | 1.56 |
| 2017 | -5.80 |
| 2016 | -20.41 |
| 2015 | -8.20 |
Debt profile data table
| Year | Financial leverage |
|---|---|
| 2024 | 2.76 |
| 2023 | 3.59 |
| 2022 | 2.83 |
| 2021 | 4.79 |
| 2020 | 5.80 |
| 2019 | 1.96 |
| 2018 | 1.61 |
| 2017 | 2.04 |
| 2016 | 2.07 |
| 2015 | 1.91 |
The figures shown in the Profit Margins table EBITDA column are quoted in the currency of the stock selected.
